Cigna’s Evernorth Pushes for Increased Humira Biosimilar Adoption

1. Cigna's Evernorth, a healthcare services division, has taken steps to encourage the use of Humira biosimilars, aiming to increase patient access and reduce healthcare costs.
2. Humira, an autoimmune disease treatment produced by AbbVie, is one of the world's best-selling drugs. Its high cost has led to the development of biosimilars, which are less expensive alternatives.
3. Evernorth's move is expected to promote competition in the market, potentially leading to lower prices for patients and payers.
4. By advocating for biosimilars, Evernorth aims to improve patient access to affordable treatments while maintaining high-quality care.
5. The shift towards biosimilars could have significant implications for AbbVie, as Humira is a major source of revenue for the company.
6. This decision aligns with Cigna's broader strategy to improve healthcare affordability and outcomes for its customers.